Skip to main navigation
  • Investor Home
  • News & Presentations
    News Events Presentations
  • Governance
    Governance Overview Board of Directors Leadership Our ESG Philosophy
  • Financials
    SEC Filings Quarterly Results Annual Reports
  • Stock Information
    Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
  • Resources
    Pipeline Investor FAQs Email Alerts Contact IR

News Releases


Jun 06, 2023

Arcutis to Present at Upcoming Investor Conference

Read More

Jun 05, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More

May 24, 2023

Arcutis Announces Leadership Transition

Read More

May 09, 2023

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

Read More

May 05, 2023

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More

May 02, 2023

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for

Read More

Apr 28, 2023

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psor

Read More

Apr 25, 2023

Arcutis to Report First Quarter Financial Results

Read More

Apr 18, 2023

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment

Read More
  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »
Displaying 1 - 9 of 21
Print Page
RSS Feeds
Email Alerts
Search
Arcutis Biotherapeutics logo
  • Contact

 (805) 418-5006
 emcintyre@arcutis.com

  • Legal Disclaimer
  • Privacy Notice
  • Cookie Settings

Social Links

  • LinkedIn
  • Twitter
© 2023 Arcutis Biotherapeutics